Amarin | AMRN - Operating Expenses

Stock Price
14.89
Daily Change
-0.11 -0.73%
Monthly
10.26%
Yearly
34.71%
Q1 Forecast
14.47

Amarin reported $51.37M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD -2.64B 12.35B Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amarin USD 51.37M 14.6M Sep/2025
AstraZeneca USD 16.69B 5.74B Sep/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
Halozyme Therapeutics USD 136.34M 13.06M Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Neurocrine Biosciences USD 555.6M 13.7M Sep/2025
Novartis USD 9.86B 115M Sep/2025